Diabetes Care, Vol 7, Issue 2 188-199, Copyright © 1984 by American Diabetes Association

ARTICLES

Insulin pharmacokinetics

C Binder, T Lauritzen, O Faber and S Pramming

Where adjustments of diet, physical activity, and dosage of insulin are well known to diabetologists and diabetic patients, present-day knowledge of factors of importance to the pharmacokinetics of insulin is frequently ignored. The pharmacokinetics of insulin comprise the absorption process, the distribution including binding to circulating insulin antibodies, if present, and to insulin receptors, and its ultimate degradation and excretion. The distribution and metabolism of absorbed insulin follow that of endogenous insulin. The distribution and metabolism cannot be actively changed, except in the case of circulating insulin antibodies, which in rare cases also may cause insulin resistance. The use of insulin preparation of low immunogeneity will avoid or reduce this course of variation in action. The absorption process, the detailed mechanisms of which are still unknown, is influenced by many variables where some can be controlled, thereby reducing the intrapatient variability in insulin absorption, which may reach 35%, causing a corresponding metabolic lability. Besides the known differences in timing among different preparations, the size of dose, the injected volume, and the insulin concentration are determinants of absorption role. Fortuitous injection technique contributes to variance, as do changes in blood flow of the injected tissue. This may be induced by changes in ambient temperature, exercise of injected limb, or local massage. Regional differences are also due to differences in blood flow. Serum insulin peaks may peak up to 1 h after injection of soluble insulin into the thigh versus into the abdominal wall. Local degradation of insulin seems of less importance but may, in rare cases, be the cause of high insulin "requirements." Available evidence is reviewed and the importance of implementing the consequences in the daily care of the insulin-treated patient is emphasized.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Pickup and E. Renard Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S140 - S145. [Abstract] [Full Text] [PDF]

				T. Berhe, D. Postellon, B. Wilson, and R. Stone Feasibility and safety of insulin pump therapy in children aged 2 to 7 years with type 1 diabetes: a retrospective study. Pediatrics, June 1, 2006; 117(6): 2132 - 2137. [Abstract] [Full Text] [PDF]

				J-W Chen, J Frystyk, T Lauritzen, and J S Christiansen Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes Eur. J. Endocrinol., December 1, 2005; 153(6): 907 - 913. [Abstract] [Full Text] [PDF]

				S. Nielsen, D. Kain, E. Szudzik, S. Dhindsa, R. Garg, and P. Dandona Use of Continuous Subcutaneous Insulin Infusion Pump in Patients With Type 2 Diabetes Mellitus The Diabetes Educator, November 1, 2005; 31(6): 843 - 848. [Abstract] [Full Text] [PDF]

				M. Davies, F. Storms, S. Shutler, M. Bianchi-Biscay, R. Gomis, and for the AT.LANTUS Study Group Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine Diabetes Care, June 1, 2005; 28(6): 1282 - 1288. [Abstract] [Full Text] [PDF]

				K. Stoneking Initiating basal insulin therapy in patients with type 2 diabetes mellitus Am. J. Health Syst. Pharm., March 1, 2005; 62(5): 510 - 518. [Abstract] [Full Text] [PDF]

				T. Heise, L. Nosek, B. B. Ronn, L. Endahl, L. Heinemann, C. Kapitza, and E. Draeger Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes Diabetes, June 1, 2004; 53(6): 1614 - 1620. [Abstract] [Full Text] [PDF]

				B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]

				D. L. Trence, J. L. Kelly, and I. B. Hirsch The Rationale and Management of Hyperglycemia for In-Patients with Cardiovascular Disease: Time for Change J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2430 - 2437. [Abstract] [Full Text] [PDF]

				R. Amin, K. Ross, C. L. Acerini, J. A. Edge, J. Warner, and D. B. Dunger Hypoglycemia Prevalence in Prepubertal Children With Type 1 Diabetes on Standard Insulin Regimen: Use of Continuous Glucose Monitoring System Diabetes Care, March 1, 2003; 26(3): 662 - 667. [Abstract] [Full Text] [PDF]

				A. D. Perera, C. Kapitza, L. Nosek, R. S. Fishman, D. A. Shapiro, T. Heise, and L. Heinemann Absorption and Metabolic Effect of Inhaled Insulin: Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes Diabetes Care, December 1, 2002; 25(12): 2276 - 2281. [Abstract] [Full Text] [PDF]

				J. H. DeVries, F. J. Snoek, P. J. Kostense, N. Masurel, and R. J. Heine A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control Diabetes Care, November 1, 2002; 25(11): 2074 - 2080. [Abstract] [Full Text] [PDF]

				E. Riu, A. Mas, T. Ferre, A. Pujol, L. Gros, P. Otaegui, L. Montoliu, and F. Bosch Counteraction of Type 1 Diabetic Alterations by Engineering Skeletal Muscle to Produce Insulin: Insights From Transgenic Mice Diabetes, March 1, 2002; 51(3): 704 - 711. [Abstract] [Full Text] [PDF]

				H. Dong, J. Altomonte, N. Morral, M. Meseck, S. N. Thung, and S. L.C. Woo Basal Insulin Gene Expression Significantly Improves Conventional Insulin Therapy in Type 1 Diabetic Rats Diabetes, January 1, 2002; 51(1): 130 - 138. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				F. Holleman and J. B.L. Hoekstra Insulin Lispro N. Engl. J. Med., July 17, 1997; 337(3): 176 - 183. [Full Text] [PDF]

				V. Peragallo-Dittko Aspiration of the Subcutaneous Insulin Injection: Clinical Evaluation of Needle Size and Amount of Subcutaneous Fat The Diabetes Educator, January 1, 1995; 21(4): 291 - 296. [PDF]

				S. M. Strowig Initiation and Management of Insulin Pump Therapy The Diabetes Educator, January 1, 1993; 19(1): 50 - 58. [PDF]

				A. M. Albisser and M. Sperlich Adjusting Insulins The Diabetes Educator, January 1, 1992; 18(3): 211 - 219. [PDF]

				J. H. Anderson and R. K. Campbell Pharmacy Update: Mixing Insulins in 1990 The Diabetes Educator, January 1, 1990; 16(5): 380 - 387. [PDF]

				C. Zehrer, R. Hansen, and J. Bantle Reducing Blood Glucose Variability by Use of Abdominal Insulin Injection Sites The Diabetes Educator, January 1, 1990; 16(6): 474 - 477. [PDF]

				J. S. Skyler Intensive Insulin Therapy: A Personal and Historical Perspective The Diabetes Educator, January 1, 1989; 15(1): 33 - 39. [PDF]